Slide 1 - Patterns of Care in Medical Oncology
Adjuvant Systemic Therapy for Breast Cancer
Slide 2 - Use of Computer Models in Clinical Practice
Slide 3 - Clinical Use of Oncotype DX Assay
Slide 4 - Clinical Use of Oncotype DX Assay
Slide 5 - Adjuvant Hormonal Therapy for ER/PR-Positive, Node-Positive Disease
Slide 6 - Adjuvant Hormonal Therapy for ER/PR-Positive, Node-Positive Disease (continued)
Slide 7 - Adjuvant Hormonal Therapy for ER/PR-Positive, Node-Positive Disease (continued)
Slide 8 - Use of Adjuvant Aromatase Inhibitors
Slide 9- Use of Adjuvant Aromatase Inhibitors
Slide 10 - Tolerability of Adjuvant Endocrine Therapy
Slide 11- Sequencing Aromatase Inhibitors after Two Years of Tamoxifen
Slide 12- Sequencing Aromatase Inhibitors after Two Years of Tamoxifen (continued)
Slide 13 - Endocrine Therapy after Five Years of Tamoxifen
Slide 14 - Endocrine Therapy after Five Years of Tamoxifen (continued)
Slide 15 - Sequencing Aromatase Inhibitors after Anastrozole
Slide 16 - Endocrine Therapy after Five Years of Anastrozole
Slide 17 - Bone Mineral Density and Adjuvant Endocrine Therapy
Slide 18 - Bone Mineral Density and Adjuvant Endocrine Therapy
Slide 19 - Bone Mineral Density and Adjuvant Aromatase Inhibitors
Slide 20 - Use of Aromatase Inhibitors in Premenopausal Women
Slide 21 - Use of Aromatase Inhibitors in Premenopausal Women
Slide 22 - Use of Aromatase Inhibitors in Premenopausal Women
Slide 23 - Approach to Adjuvant Therapy for ER/PR-Positive, Node-Negative Disease
Slide 24 - Approach to Adjuvant Chemotherapy for ER/PR-Positive, Node-Negative Disease
Slide 25 - Approach to Adjuvant Chemotherapy for ER/PR-Positive, Node-Negative Disease (continued)
Slide 26 - Approach to Adjuvant Endocrine Therapy for ER/PR-Positive, Node-Negative Disease
Slide 27 - Approach to Adjuvant Endocrine Therapy for ER/PR-Positive, Node-Negative Disease (continued)
Slide 28 - Approach to Adjuvant Therapy for ER/PR-Positive, Node-Positive Disease
Slide 29 - Approach to Adjuvant Chemotherapy for ER/PR-Positive, Node-Positive Disease
Slide 30 - Approach to Adjuvant Chemotherapy for ER/PR-Positive, Node-Positive Disease (continued)
Slide 31 - Adjuvant Hormonal Therapy for ER/PR-Positive, Node-Positive Disease
Slide 32 - Adjuvant Hormonal Therapy for ER/PR-Positive, Node-Positive Disease (continued)
Slide 33 - Adjuvant Chemotherapy for ER/PR-Negative, HER2-Negative Disease: Positive Lymph Nodes
Slide 34 - Adjuvant Chemotherapy for ER/PR-Negative, HER2-Negative Disease: Positive Lymph Nodes (continued)
Slide 35 - Adjuvant Chemotherapy for ER/PR-Negative, HER2-Negative Disease: Positive Lymph Nodes (continued)
Slide 36 - Clinical Use of Adjuvant Taxantes
Slide 37 - Clinical Use of Adjuvant Taxantes
Slide 38 - Selection of Taxanes
Slide 39 - Taxanes with AC in the Adjuvant Setting
Slide 40 - Use of Nanoparticle Paclitaxel
Slide 41 - Allergic Reactions to Taxanes
Slide 42 - Use of Steroid Premedication with Adjuvant Taxanes
